Clindamycin

How to order Clindamycin

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Clindamycin on Prescriptsy

Clindamycin is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Clindamycin is a lincosamide antibiotic that has been used in clinical practice since the 1960s and remains an important treatment option for a range of serious bacterial infections in the United Kingdom.

It is active against many Gram-positive aerobic bacteria and most clinically significant anaerobic organisms, making it valuable in skin and soft tissue infections, bone and joint infections, dental and orofacial infections, intra-abdominal infections, and acne vulgaris.

Clindamycin is available as oral capsules, solution for injection, and topical preparations (gel and lotion).

This page provides a detailed clinical overview of clindamycin, including its mechanism of action, licensed indications, dosing guidance, side effects, the important risk of Clostridioides difficile infection, safety warnings, and information about obtaining a prescription in the UK.

Clindamycin is classified as a prescription-only medicine (POM) in the UK.

Important safety information about clindamycin

Clindamycin has an important association with Clostridioides difficile-associated diarrhoea (CDAD), which can be severe and potentially life-threatening. Before reading further, note the following key points.

• If you develop diarrhoea during or for several weeks after a course of clindamycin, stop the antibiotic and contact your GP immediately. Do not take anti-diarrhoeal medicines such as loperamide.
• Clindamycin should generally be reserved for infections where first-line antibiotics are unsuitable, or where clindamycin offers specific clinical advantages (such as bone penetration or anaerobic coverage).
• Complete the full course as prescribed. Do not stop early because you feel better, as incomplete treatment may lead to treatment failure and antibiotic resistance.
• Inform your prescriber if you have any history of gastrointestinal disease, particularly inflammatory bowel disease or previous C. difficile infection.

What infections does clindamycin treat

Clindamycin is used to treat a variety of infections caused by susceptible organisms. The main licensed and commonly used indications in the UK include the following.

Skin and soft tissue infections

Clindamycin is effective against Staphylococcus aureus and Streptococcus pyogenes, the most common causes of cellulitis, erysipelas, wound infections, abscesses, and impetigo.

It is frequently used as an alternative to flucloxacillin in patients with penicillin allergy.

Clindamycin also has activity against community-acquired MRSA (CA-MRSA) strains in regions where these are prevalent, though sensitivity testing should guide therapy.

Bone and joint infections

Clindamycin penetrates bone tissue effectively, achieving concentrations in bone that are 40 to 75% of simultaneous serum levels.

This property makes it a valuable option for osteomyelitis (bone infection) and septic arthritis, particularly when caused by staphylococci.

Treatment of bone infections typically requires prolonged courses of 4 to 6 weeks or longer, often initiated intravenously and then switched to oral therapy (IV-to-oral switch) once the patient is clinically stable.

Dental and orofacial infections

Severe dental infections, including dental abscesses, Ludwig angina, and periorbital cellulitis of dental origin, often involve anaerobic bacteria.

Clindamycin is recommended as a second-line agent for dental infections in the BNF, particularly for patients with penicillin allergy.

It covers the mixed aerobic and anaerobic flora characteristic of odontogenic infections.

Intra-abdominal and pelvic infections

In combination with an aminoglycoside (such as gentamicin), clindamycin has historically been used to treat peritonitis, pelvic inflammatory disease (PID), and other intra-abdominal infections involving anaerobic organisms, particularly Bacteroides fragilis.

Modern practice may favour other regimens, but clindamycin combinations remain an option in certain clinical scenarios.

Acne vulgaris

Topical clindamycin 1% gel or lotion is one of the most commonly prescribed topical antibiotics for inflammatory acne in the UK.

It reduces the population of Cutibacterium acnes (formerly Propionibacterium acnes) in sebaceous follicles and has anti-inflammatory properties.

NICE Clinical Knowledge Summaries and dermatological guidelines recommend using topical clindamycin in combination with benzoyl peroxide to reduce the risk of antibiotic resistance development.

How clindamycin works: mechanism of action

Clindamycin inhibits bacterial protein synthesis by binding to the 23S rRNA component of the 50S ribosomal subunit.

This blocks the translocation step in the elongation cycle, preventing the bacterium from assembling the amino acid chains needed to form functional proteins.

Depending on the drug concentration, the bacterial species, and the inoculum size, clindamycin may be bacteriostatic (inhibiting growth) or bactericidal (killing bacteria).

Clindamycin has a post-antibiotic effect, meaning that bacterial growth remains suppressed for a period after drug levels fall below the minimum inhibitory concentration (MIC).

This property supports intermittent dosing schedules.

The drug is well absorbed orally (approximately 90% bioavailability), widely distributed into tissues including bone, lungs, pleural fluid, peritoneal fluid, and abscesses, and extensively metabolised by the liver.

It does not cross the blood-brain barrier in therapeutically useful concentrations.

Resistance to clindamycin may be constitutive or inducible.

Constitutive resistance is mediated by methylation of the ribosomal binding site (erm genes), conferring cross-resistance to macrolides and streptogramin B (MLSB resistance).

Inducible resistance can be detected by the D-test in the microbiology laboratory, where apparent erythromycin resistance may predict clindamycin treatment failure despite in-vitro susceptibility.

Your prescriber and microbiologist will interpret sensitivity results in this context.

Clinical evidence and guidelines

The BNF lists clindamycin for the treatment of staphylococcal bone and joint infections, peritonitis, and as an alternative in penicillin-allergic patients for skin, soft tissue, and dental infections.

NICE Clinical Knowledge Summaries on cellulitis, impetigo, and acne vulgaris include clindamycin in their recommended treatment pathways.

Public Health England (now UKHSA) antimicrobial prescribing guidelines recommend clindamycin with caution, emphasising the importance of C.

difficile risk stratification, particularly in elderly patients and those with recent healthcare exposure.

For acne, the NICE pathway on acne vulgaris recommends topical clindamycin combined with benzoyl peroxide as a first-line topical option for moderate inflammatory acne.

Oral clindamycin is not routinely used for acne in the UK due to the C.

difficile risk; oral tetracyclines (such as doxycycline or lymecycline) are preferred for systemic acne treatment.

Clostridioides difficile: understanding the risk

Clindamycin is classified as a high-risk antibiotic for C. difficile infection by UKHSA and NHS antimicrobial stewardship programmes.

Disruption of the normal colonic microbiota by clindamycin creates an environment favourable for C. difficile colonisation, toxin production, and symptomatic infection.

The risk persists for several weeks after completing a course of clindamycin.

C. difficile infection ranges in severity from mild, self-limiting diarrhoea to fulminant pseudomembranous colitis with toxic megacolon, colonic perforation, sepsis, and death.

Risk factors for severe disease include advanced age (over 65 years), recent hospitalisation, immunosuppression, proton pump inhibitor use, and prior antibiotic exposure.

NHS antimicrobial stewardship policies aim to minimise unnecessary clindamycin prescribing, particularly in these high-risk groups.

The importance of this risk cannot be overstated. Patients must be informed about the signs of C.

difficile infection (watery or bloody diarrhoea, cramping abdominal pain, fever) and instructed to seek medical attention immediately if these develop.

Antiperistaltic agents such as loperamide must be avoided, as they may worsen colonic distension and toxin retention.

Side effects of clindamycin

Common side effects

Gastrointestinal disturbance is the most frequently reported adverse effect of systemic clindamycin. Nausea, vomiting, abdominal pain, and diarrhoea (not attributable to C.

difficile) occur in approximately 2 to 20% of patients and are usually mild and self-limiting.

Taking capsules with a full glass of water and with food may reduce nausea.

Serious side effects

Pseudomembranous colitis caused by C. difficile is the most serious adverse effect and has been discussed in detail above.

Hepatotoxicity, presenting as abnormal liver function tests or clinical jaundice, has been reported uncommonly. Periodic monitoring of liver function is recommended during prolonged systemic therapy.

Blood dyscrasias, including neutropenia, thrombocytopenia, and agranulocytosis, are rare. Serious hypersensitivity reactions including anaphylaxis, erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis have been reported very rarely.

Topical clindamycin side effects

Local skin reactions including dryness, peeling, burning, and erythema are common with topical clindamycin preparations. These are usually mild and improve with continued use.

Although systemic absorption from topical application is low, C. difficile diarrhoea has been reported in rare cases with topical use, and patients should be informed of this possibility.

When to seek medical advice

Contact your GP or NHS 111 if you develop diarrhoea (more than 3 loose stools in 24 hours), blood in your stools, severe abdominal pain, skin rash, or signs of allergic reaction (facial swelling, difficulty breathing).

Seek emergency care (call 999 or attend A&E) if you develop signs of severe colitis, anaphylaxis, or a severe skin reaction.

Report any suspected adverse reactions via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk .

Warnings and precautions

Gastrointestinal disease

Clindamycin should be used with extreme caution, if at all, in patients with a history of inflammatory bowel disease (ulcerative colitis or Crohn's disease) or previous C.

difficile infection. These patients are at markedly increased risk of C. difficile colitis. Your prescriber should explore alternative antibiotics before prescribing clindamycin in these groups.

Hepatic impairment

Clindamycin is extensively metabolised in the liver. Patients with moderate to severe hepatic impairment may have increased plasma concentrations and require dose adjustment or enhanced monitoring. Liver function tests should be checked at baseline and periodically during prolonged treatment.

Renal impairment

No dose adjustment is typically required in patients with renal impairment, as renal excretion accounts for only a minor fraction of clindamycin elimination.

However, the injectable formulation contains benzyl alcohol, which should be used with caution in patients with severe renal failure.

Pregnancy and breastfeeding

Clindamycin crosses the placenta and is present in breast milk. It should be used during pregnancy only if the expected benefit justifies the potential risk.

Topical clindamycin for acne is generally avoided during pregnancy as a precautionary measure, and alternative treatments should be considered.

Breastfeeding mothers should discuss the risks with their prescriber; clindamycin may alter the infant's gut flora, though clinical consequences appear to be rare.

Antimicrobial stewardship

In accordance with NHS and UKHSA antimicrobial stewardship principles, clindamycin should be prescribed only when there is a clear clinical indication, when first-line agents are unsuitable, and for the shortest effective duration.

This approach helps to minimise the population-level risk of C. difficile infection and the development of antibiotic resistance.

How to get a clindamycin prescription in the UK

Clindamycin in all formulations is classified as a prescription-only medicine (POM) in the UK.

Oral and injectable clindamycin are prescribed by GPs, hospital doctors, and dentists for appropriate infections.

Topical clindamycin for acne may be prescribed by GPs, dermatologists, or authorised online prescribers following clinical assessment. All UK prescriptions are dispensed by registered pharmacies.

The standard NHS prescription charge in England is currently 9.90 pounds per item; prescriptions are free in Scotland, Wales, and Northern Ireland.

When to seek urgent medical advice

Seek urgent medical attention if during or after a course of clindamycin you develop persistent watery or bloody diarrhoea, severe abdominal pain or cramping, fever, signs of dehydration (reduced urine output, dizziness, dry mouth), or any signs of severe allergic reaction (swelling of the face, lips, tongue, or throat, difficulty breathing, widespread rash).

Call 999 or attend A&E for life-threatening symptoms. Report any suspected adverse reactions via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk .

Sources

• Clindamycin Capsules, Summary of Product Characteristics (EMC)
• Clindamycin, British National Formulary (BNF)
• NICE CKS: Cellulitis, acute
• NICE CKS: Acne vulgaris
• Antibiotics, NHS
• MHRA Yellow Card Scheme